Managing Dental Implant Planning

Managing Dental Implant Planning

Structures dental implant evaluation with bone volume assessment, prosthetic-driven planning, surgical documentation, and long-term maintenance protocols per ITI/AO treatment guidelines and FDA medical device regulations.

Why This Skill Exists

Implant failure stems from two root causes: poor patient selection and poor position planning. Placing an implant in insufficient bone, ignoring occlusal overload risk, failing to maintain adequate distance from the IAN canal, or selecting the wrong implant diameter for the restoration creates complications ranging from early failure to peri-implantitis to permanent nerve injury. This skill enforces prosthetic-driven implant planning (restoration dictates implant position, not the reverse), ensures bone volume is verified with CBCT before surgery, and structures documentation to satisfy both clinical protocols and FDA device tracking requirements (21 CFR Part 821).

Checkpoint A — Pre-Planning Verification

Required Inputs

• CBCT scan of the proposed implant site(s) — 2D radiographs alone are insufficient for implant planning per AAOMR guidelines
• Complete periodontal assessment with AAP/EFP staging/grading (uncontrolled periodontal disease is a contraindication)
• Diagnostic wax-up or digital treatment plan with proposed restoration design
• Medical history with focus on: bisphosphonate/denosumab use, uncontrolled diabetes (HbA1c > 8%), active radiation therapy, immunosuppression, smoking status, anticoagulant therapy
• Dental history of the edentulous site (reason for tooth loss, time since extraction, prior grafting)
• Diagnostic models or digital scans for prosthetic planning
• Insurance pre-authorization (when applicable) with supporting documentation

Intake Questions

1. When was the tooth extracted, and what was the reason for loss?
2. Has the patient had prior bone grafting at the site?
3. Is the patient taking bisphosphonates or denosumab (oral or IV), and for how long?
4. What is the patient's smoking status (current, former, never; quantity)?
5. What is the patient's HbA1c (if diabetic)?
6. Has the patient had radiation to the head/neck region?
7. Does the patient have parafunctional habits (bruxism, clenching)?
8. What is the prosthetic goal (single crown, bridge, overdenture, full-arch fixed)?

Step 1 — Bone Volume and Quality Assessment

Evaluate the implant site using CBCT measurements.

• Bone height: Measure available vertical bone from crest to vital structure (IAN canal, mental foramen, maxillary sinus floor, nasopalatine canal, nasal floor); minimum 10 mm preferred, absolute minimum 8 mm with short implant consideration
• Bone width: Measure buccolingual width at crestal, mid-root, and apical levels; minimum 6 mm for standard diameter implant (to maintain 1.5 mm buccal and 1 mm lingual bone around a 3.75 mm implant)
• Bone density: Classify using Misch classification (D1 dense cortical, D2 thick cortical with coarse trabecular, D3 thin cortical with fine trabecular, D4 fine trabecular with minimal cortical) — D4 bone has highest failure rate
• Vital structure distances: IAN canal (maintain minimum 2 mm safety zone), mental foramen (identify anterior loop), maxillary sinus (measure subantral bone height for sinus lift determination), incisive canal
• Deficiency classification: Seibert Class I (buccolingual loss), Class II (apicocoronal loss), Class III (combined); determines grafting requirements
• Grafting needs determination: If bone is insufficient — document type of augmentation needed (GBR with membrane, block graft, sinus lift/elevation, ridge split, distraction osteogenesis)

Step 2 — Prosthetic-Driven Planning

Plan implant position based on the final restoration, not available bone alone.

• Restoration design: Single crown, splinted crowns, fixed bridge, bar-retained overdenture, screw-retained full-arch prosthesis; document occlusal scheme
• Implant position: Plan 3D position using guided surgery software (e.g., coDiagnostiX, BlueSky, Simplant); document mesiodistal, buccolingual, and apicocoronal position relative to prosthetic tooth position
• Inter-implant spacing: Minimum 3 mm between implants; minimum 1.5 mm from implant to adjacent natural tooth
• Emergence profile: Implant platform should be 3–4 mm apical to planned gingival margin for ideal soft tissue contour
• Implant selection: Document system (manufacturer, product line), diameter (narrow 3.0–3.5 mm, standard 3.75–4.5 mm, wide 5.0–6.0 mm), length, connection type (internal hex, external hex, conical/Morse taper), surface treatment
• Surgical guide: Specify whether freehand, pilot-drill guided, or fully guided approach; document guide fabrication method (lab-based vs. in-office 3D printed)
• Loading protocol: Immediate loading (within 48 hours), early loading (1–8 weeks), conventional loading (3–6 months); document rationale for selected protocol

Step 3 — Risk Assessment and Contraindication Screening

Evaluate patient-specific and site-specific risk factors.

• Absolute contraindications: Recent MI (< 6 months), active cancer chemotherapy/radiation to site, uncontrolled bleeding disorders, IV bisphosphonate use > 3 years with MRONJ history
• Relative contraindications requiring modification: Smoking (cessation counseling required; informed consent regarding 2× failure risk), uncontrolled diabetes (HbA1c > 8%; optimize before surgery), oral bisphosphonate use (drug holiday discussion with prescribing physician per AAOMS), bruxism (nightguard requirement, wider/longer implant consideration)
• Site-specific risks: Thin biotype (increased recession risk), history of periodontitis at the site (higher peri-implantitis risk per Heitz-Mayfield 2010), previous implant failure at same site
• Occlusal risk: Cantilever loading, opposing natural dentition vs. prosthesis, parafunctional forces; document occlusal management plan (nightguard, occlusal adjustment)

Step 4 — Surgical Documentation

Record implant placement procedure with device tracking detail.

• Implant identification (FDA 21 CFR 821): Manufacturer, product name, catalog/reference number, lot number, diameter, length, surface treatment — this is a legal documentation requirement for trackable medical devices
• Surgical protocol: Incision design, flap elevation, osteotomy sequence (drill sizes and RPM/torque settings), bone density encountered, implant insertion torque (ISQ or Ncm), primary stability achieved (yes/no)
• Grafting documentation: If simultaneous grafting performed — graft material (autogenous, allograft, xenograft, alloplast), manufacturer, lot number, volume placed, membrane type and fixation
• Healing abutment or cover screw: Document which was placed and size
• Intraoperative imaging: Periapical radiograph to confirm implant position and proximity to vital structures
• Complications: Note any perforation of sinus membrane (managed with collagen membrane), fenestration/dehiscence of bone (managed with GBR), nerve proximity concerns, implant repositioning

Step 5 — Osseointegration and Prosthetic Phase

Document healing assessment and restoration delivery.

• Healing assessment: At uncovery (if two-stage protocol) — assess for osseointegration clinically (no mobility, no pain on percussion, no radiolucency around implant threads); ISQ measurement if Osstell available (ISQ > 65 generally indicates adequate integration)
• Impression and fabrication: Document impression technique (open-tray, closed-tray, digital scan body), abutment selection (stock vs. custom, material — titanium, zirconia), and prosthetic material
• Prosthesis delivery: Record fit verification (Sheffield test, single-screw test for multi-unit), occlusal contacts (light contact in centric, no contact in excursive for single implants), screw torque values per manufacturer specification, access hole restoration
• Post-delivery radiograph: Baseline periapical showing implant-abutment junction, bone levels at mesial and distal threads — this becomes the reference for future peri-implant bone level comparison

Step 6 — Maintenance Protocol

Establish long-term monitoring schedule.

• Recall interval: Every 3–6 months during first year, then frequency based on risk assessment (higher risk = more frequent recalls)
• Assessment at each recall: Probing depths (4–6 sites with plastic or titanium-tipped probe), BOP, suppuration, keratinized tissue width, occlusion, prosthesis integrity, radiographic bone levels (annual periapical)
• Peri-implant mucositis management: Mechanical debridement with non-metal instruments, CHX rinse, oral hygiene reinforcement
• Peri-implantitis indicators: BOP + progressive bone loss beyond initial remodeling (typically > 2 mm from platform after first year) — document and plan treatment (non-surgical decontamination, surgical access with decontamination and grafting)

Checkpoint B — Planning Completeness Review

• CBCT evaluation completed with bone height, width, and density documented
• Vital structure distances measured and safety zones confirmed
• Prosthetic-driven implant position planned with appropriate software or wax-up
• Implant system, diameter, length, and connection type selected with rationale
• Risk factors screened (bisphosphonates, diabetes, smoking, bruxism, periodontitis history)
• Grafting needs identified and materials/approach planned
• Surgical guide fabricated or freehand approach justified
• FDA-required device identification information documented (lot number, manufacturer, dimensions)
• Loading protocol selected with rationale
• Maintenance protocol established with recall schedule

Quality Audit

Guidelines

• CBCT is the standard of care for pre-implant assessment — never plan implant placement from panoramic or periapical radiographs alone
• Prosthetic-driven planning is mandatory: the restoration dictates the implant position; document the prosthetic plan before selecting the implant
• Maintain minimum safety distances: 2 mm from IAN canal, 1.5 mm from adjacent tooth root, 3 mm between implants
• All implant components must be documented with manufacturer, catalog number, and lot number per FDA 21 CFR Part 821 medical device tracking requirements
• Bisphosphonate patients require MRONJ risk discussion per AAOMS Position Paper; document drug name, route, duration, and shared decision-making
• Smoking increases implant failure risk approximately 2×; document smoking cessation counseling and patient's response
• Uncontrolled diabetes (HbA1c > 8%) is a relative contraindication; document discussion with patient and endocrinologist clearance
• Never load an implant that has not achieved adequate primary stability or passed osseointegration assessment
• Peri-implant bone levels at the 1-year post-loading radiograph become the permanent baseline for monitoring — ensure this radiograph is taken and filed
• Occlusal overload is a primary cause of late implant failure — document occlusal management including nightguard prescription for bruxism patients